RecruitingNCT04377854

Prognostic Value of BNP in MCS - a 25 Year Follow up Study

The Prognostic Value of proBNP in Patients Supported With Durable Mechanical Circulatory Assist Devices - a 25 Year Follow up Study.

Sponsor

Rigshospitalet, Denmark

Enrollment

1,000 participants

Start Date

Sep 18, 2020

Study Type

OBSERVATIONAL

Conditions

Heart Failure Prognosis Left Ventricular Assist Device Durable Mechanical Support Device

Summary

A biobank has been created to investigate the prognostic value of biomarkers (mainly BNP) in patients implanted with durable mechanical assist devices comparing patients with advanced HF supported by MCS with those who are transplanted and those who remain on optimal medical therapy. Patients will be followed up for 25 years after inclusion.

Eligibility

Min Age: 18 Years

Inclusion Criteria2

All patients referred for evaluation for advanced HF treatment at the Rigshospital in Denmark
Age\>18 years

Exclusion Criteria1

No consent

Interventions

OTHERObservation. No intervention per se.

Observation. No intervention (no collection of blood).

OTHER2) Observation and collection and of blood sample

All patients evaluated for adv HF (HTX/LVAD) will be offered to contribute to this database; Blood samples will be collected from all at baseline. Patients receiving LVAD will contribute on a yearly basis (or until withdrawal of consent). For other patients no further blood will be collected unless they receive an LVAD at a later point.